Our website uses cookies to bring you an easy and personalised browsing experience. By continuing, you consent to our cookie policy on this device. For More info, please see our Privacy Statement

ICECaP

Engaging a community of investigators and patient representatives to create and develop a global strategic approach to decrease deaths from prostate cancer

Objectives and Aims

01

Greater integration of all scientific disciplines, pharma companies, co-operative groups, regulatory agencies and patient representatives for designing and conducting and analyzing clinical trial and registry data. This will limit needless duplication while preserving and harnessing opportunities for assessing requisite reproducibility of findings.

02

Integration of new endpoints into clinical trials that expedite the determination of whether new therapies improve the outcome (survival and quality of life) of men with high risk, localized and metastatic hormone-sensitive prostate cancer.

03

Validation of putative biomarkers (tissue or blood-based, imaging) to help assign the right therapy for the right patient at the right time.

Input your text in this area

Funding Acknowledgement

The ICECaP collaboration was made possible by the lead investment from the Prostate Cancer Foundation (PCF) in 2013 as part of their Challenge Award grant mechanisms.

Christopher Sweeney, ICECaP Principal Investigator
Presenting plans at Prostate Cancer Foundation Scientific Retreat. Further funding has been achieved as part of an academic-pharma partnership.

ICECaP1

2013-2017 Funding period

Prostate Cancer Foundation Challenge Award
Millennium Pharmaceuticals (via PCF)
Janssen (via PCF)
Sanofi (via PCF)
Astellas / Medivation
Sotio (via PCF)

ICECaP2

2018-Ongoing Funding period

Janssen (via PCF)
Dendreon (Via PCF)
Sanofi (via PCF)
Astellas / Pfizer
Bayer

ICECaP Biology

Funding / In-kind support

DECIPHER Biosciences
U.S. Department of Defense
National Cancer Institute
Prostate Cancer UK
Prostate Cancer Foundation
John Black Charitable Foundation
Prostate Cancer Research
Benioff Initiative for Prostate Cancer Research

STOPCAP M1

Prostate Cancer UK Innovations award
(for efficacy reviews)
PCF Challenge Award
(for surrogacy/prognosis analyses)

Health Economics

ANZUP in collaboration with the Centre for Health Economics Research and Evaluation (University of Technology Sydney), with funding support from:

Astellas Australia
Janssen Australia

Movember - ICECaP Collaboration.

Movember is partnering with the ICECaP Consortium to leverage the natural alignment of our shared goal to accelerate global progress on developing a strategic approach to significantly reduce the number of men dying from prostate cancer.

The in-kind support from the Movember team for overall logistics and communication will provide the requisite platforms for dissemination to and engagement with all stakeholders.

Read about Projects

Email Us